Clinical trials: Lesion
Stents, Coronary Artery Disease
SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
This study is divided into 5 arms: 1. Randomized Clinical Trial (RCT): Prospective, randomized, active-controlled, single blind, parallel two-arm multi-center clinical trial in the United States (US) comparing XIENCE V®…
- Conditions
- Stents, Coronary Artery Disease, Total Coronary Occlusion, Coronary Artery Restenosis
- Trial name
- NCT00180479
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent, TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent
- Where
- 65 sites in United States
- Volunteers
- 1,002 people
- Sponsor
- Abbott Medical Devices
Alopecia Areata
An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata
Alopecia areata (AA) is a common disease of the immune system, known as an "autoimmune" disease. In this disease, the immune system mistakenly destroys the hair follicle, causing hair to fall out.
- Trial name
- NCT02018042
- Testing
- Abatacept
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Columbia University
Osteoarthritis Pain of the Knee
A 12-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Osteoarthritis Pain of the Knee
A 12-week, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 study to Evaluate the Efficacy and Safety of HP-5000 in Subjects with Osteoarthritis (OA) Pain of the Knee
- Trial name
- NCT04683627
- Testing
- Diclofenac sodium active topical patch
- Where
- 10 sites in United States
- Volunteers
- 370 people
- Sponsor
- Noven Pharmaceuticals, Inc.
Psoriatic Arthritis
PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis and a qualifying psoriasis lesion.
- Trial name
- PALACE 3 (NCT01212770)
- Testing
- Apremilast 20mg, Apremilast 30mg
- Where
- 91 sites in United States, Australia and 14 more
- Volunteers
- 505 people
- Sponsor
- Amgen
Skin Care
To Evaluate Skin Irritation and Skin Sensitisation of Developmental Cosmetic Facial Products
The aim of this study is to assess irritant or allergic response of 3 developmental cosmetic facial products following a conventional human repeated insult patch test methodology for 6 weeks.
- Trial name
- NCT04007159
- Testing
- Serum, Lotion, Cream
- Where
- Brazil
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Atherosclerosis, Cardiovascular Diseases
Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions
This study will compare medical therapy plus stenting of hemodynamically significant renal artery stenoses versus medical therapy alone in patients with systolic hypertension and renal artery stenosis.
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Hypertension, Renovascular, Renal Artery Obstruction
- Trial name
- CORAL (NCT00081731)
- Testing
- Atacand/HCT, Caduet, GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting)
- Where
- United States
- Volunteers
- 947 people
- Sponsor
- Baim Institute for Clinical Research
Pigmented Skin Lesion of Suspected Benign Nature
A Clinical Evaluation of a Novel Multi-Wavelength Laser for Benign Pigmented Lesion Removal
To evaluate the safety and efficacy of an investigational version of the Cutera enlightenTM laser that offers multiple wavelengths for removal of benign pigmented lesions.
- Trial name
- NCT02635880
- Testing
- Investigational Enlighten Device
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Cutera Inc.
Postherpetic Neuralgia, Complex Regional Pain Syndromes (CRPS)
A Confirmatory Study of Fentanyl in Participants With Post-herpetic Neuralgia, Complex Regional Pain Syndrome or Postoperative Pain Syndrome
The purpose of this study is to evaluate the efficacy and safety of fentanyl in opioid-naive participants with post-herpetic neuralgia, complex regional pain syndrome or post-operative pain syndrome who cannot obtain a sufficient…
- Conditions
- Postherpetic Neuralgia, Complex Regional Pain Syndromes (CRPS), Postoperative Pain
- Trial name
- NCT01008553
- Testing
- Fentanyl
- Where
- 79 sites in Japan
- Volunteers
- 258 people
- Sponsor
- Janssen Pharmaceutical K.K.
Papillomavirus Infections, Cervical Intraepithelial Neoplasia
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
Background: Human papillomavirus (HPV) can cause cervical, throat, anal, and genital cancers. Cancers caused by HPV have an HPV protein called E7 inside of their cells.
- Conditions
- Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms
- Trial name
- NCT02858310
- Testing
- E7 TCR cells, Aldesleukin, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 224 people
- Sponsor
- National Cancer Institute (NCI)
Kaposi's Sarcoma
Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT
The purpose of this study (NAV3-12) is to determine the dissemination and localization of Tc 99m tilmanocept by SPECT and SPECT/CT imaging in subjects with confirmed cutaneous KS.
- Trial name
- NCT02201420
- Testing
- Tc 99m tilmanocept
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Navidea Biopharmaceuticals
Atrial Fibrillation
Evaluation of the CIRCA Monitoring System in Prevention of Esophageal Lesions Following RFCA
The purpose of this study is to determine if the use of Circa™ temperature monitoring system during ablation procedures will reduce the risk of esophageal lesions or damage.
- Trial name
- CIRCA-EGD (NCT02467166)
- Testing
- Circa™ Probe
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Diego
Alzheimer's Disease
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
The core study assessed the efficacy of a higher dose of rivastigmine 13.3 mg/24 h transdermally (15 cm^2 patch) compared to a lower dose of the rivastigmine 4.6 mg/24 h transdermally (5 cm^2 patch) in patients with Severe…
- Trial name
- ACTION (NCT00948766)
- Testing
- Rivastigmine 4.6 mg/24 h (5 cm^2), Rivastigmine 9.5 mg/24 h (10 cm^2), Rivastigmine 13.3 mg/24 h (15 cm^2)
- Where
- 95 sites in United States, Puerto Rico
- Volunteers
- 716 people
- Sponsor
- Novartis
Hemorrhage, Pelvic Fracture
Pre-hospital Advanced Therapies for Control of Hemorrhage - Pelvis
The purpose of this study is to determine whether the use of pelvic binders in the ambulance setting improves outcomes including mortality in patients with pelvic fractures.
- Trial name
- PATCH (NCT02855060)
- Testing
- Pelvic Binder
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Wake Forest University Health Sciences
Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia
VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions
This phase II trial studies the use of human papillomavirus (HPV) deoxyribonucleic acid (DNA) plasmids therapeutic vaccine VGX-3100 (VGX-3100) and electroporation in treating patients with human immunodeficiency virus…
- Conditions
- Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive
- Trial name
- NCT03603808
- Testing
- Electroporation, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, Laboratory Biomarker Analysis
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 44 people
- Sponsor
- AIDS Malignancy Consortium
Myocardial Ischemia, Coronary Artery Stenosis
ABSORB EXTEND Clinical Investigation
The ABSORB EXTEND trial is to continue the assessment of the safety and performance of the ABSORB Bioresorbable Vascular Scaffold (BVS) System ABSORB BVS is currently in development at Abbott Vascular.
- Conditions
- Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease
- Trial name
- ABSORB EXTEND (NCT01023789)
- Testing
- ABSORB BVS
- Where
- 56 sites in Argentina, Australia and 23 more
- Volunteers
- 812 people
- Sponsor
- Abbott Medical Devices
Syncope
Diagnostic Yield of an Ambulatory Patch Monitor in Unexplained Emergency Department Syncope: A Pilot Study (PATCH-ED)
Syncope is a common Emergency Department (ED) presentation but the underlying diagnosis is not apparent in 60% of patients after assessment and serious adverse event rate is 7% at one month with most having acute cardiovascular…
- Trial name
- PATCH-ED (NCT02683174)
- Testing
- Novel ambulatory patch (ZIO® XT Patch), BNP and hs-troponin I at 0 and 3 hours post ED attendance
- Where
- United Kingdom
- Volunteers
- 86 people
- Sponsor
- NHS Lothian
Lesion in Body Region
Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)
The trial aimed at evaluating the efficacy and the safety of gadopiclenol for body Magnetic resonance Imaging (MRI)
- Trial name
- PROMISE (NCT03986138)
- Testing
- gadopiclenol, Gadobutrol 1 MMOLE/ML Intravenous Solution
- Where
- 33 sites in United States, Bulgaria and 9 more
- Volunteers
- 324 people
- Sponsor
- Guerbet
Actinic Keratosis
Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients
This is a randomized, vehicle controlled, active comparator, parallel group, study with a total duration of 24 weeks including screening and follow-up.
- Trial name
- NCT02404389
- Testing
- Investigational Treatment, Active comparator
- Where
- 10 sites in Austria, Denmark and 3 more
- Volunteers
- 82 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Total Occlusion of Coronary Artery, Coronary Occlusion
ABSORB FIRST is a Registry Designed to Evaluate the Safety and Performance of Absorb Bioresorbable Vascular Scaffold (Absorb BVS) Used in Real-world Patients.
ABSORB FIRST is a prospective, multi-center registry. The objectives of the study are to: Provide ongoing post-market surveillance for documentation of safety, performance and clinical outcomes of the Absorb BVS (Bioresorbable…
- Conditions
- Chronic Total Occlusion of Coronary Artery, Coronary Occlusion, Coronary Artery Disease, Coronary Artery Restenosis
- Trial name
- NCT01759290
- Testing
- Absorb Bioresorbable Vascular Scaffold
- Where
- Belgium
- Volunteers
- 1,800 people
- Sponsor
- Abbott Medical Devices
Facial Papulopustular Rosacea
A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
The primary objectives of this study are to determine the efficacy and safety of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea.
- Trial name
- NCT04608500
- Testing
- FMX103 minocycline foam 1.5%, Vehicle foam
- Where
- 46 sites in United States
- Volunteers
- 771 people
- Sponsor
- Vyne Therapeutics Inc.